Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 3/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31412623 | 1.00 | SLC6A3 (0.44) | SLC6A3SLC6A2SLC6A4HTR3AHTR2C | |
| SCHEMBL6919767 | 0.80 | — | — | |
| SCHEMBL27389116 | 0.80 | KCNH2 (0.41) | SLC6A3SLC6A2SLC6A4HTR2CHTR2A | |
| Hydrochloric Acid SCHEMBL1991970 | 0.79 | — | — | |
| SCHEMBL31478255 | 0.78 | SLC6A3 (0.57) | SLC6A3SLC6A2SLC6A4HTR3A | |
| SCHEMBL17514103 | 0.76 | SLC6A3 (0.44) | SLC6A3SLC6A2SLC6A4HTR3AHTR2C | |
| SCHEMBL31412663 | 0.76 | SLC6A3 (0.44) | SLC6A3SLC6A2SLC6A4HTR3AHTR2C | |
| SCHEMBL13580670 | 0.76 | HTR2C (0.45) | SLC6A3SLC6A2SLC6A4HTR3AHTR2C | |
| SCHEMBL31412664 | 0.76 | SLC6A3 (0.44) | SLC6A3SLC6A2SLC6A4HTR3AHTR2C | |
| SCHEMBL15729989 | 0.76 | SLC6A3 (0.44) | SLC6A3SLC6A2SLC6A4HTR3AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025045746-A1 | PYRAZOLE DERIVATIVES AS SARM1 INHIBITORS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2025-03-06 | — | — | WO | disclosed |